Parmax Pharma Reports Positive Financial Results for Q1 FY25, Indicates Growth Potential

Parmax Pharma, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending March 2024. The company’s stock has been given a ‘Sell’ call by MarketsMOJO.

According to the financial report, Parmax Pharma has shown a flat performance in the quarter, but there has been an improvement in its score from -16 to 4 in the last three months. This indicates a positive trend for the company.

One of the key factors contributing to this improvement is the company’s net sales, which have grown by 55.27% year on year, reaching Rs 12.08 crore in the first half of the year. The near-term sales trend for Parmax Pharma is also very positive.

In terms of profitability, the company has shown a strong performance in the last quarter, with its operating profit (PBDIT) reaching its highest at Rs 0.52 crore in the last five quarters. The trend for operating profit is also positive in the near term. Similarly, the company’s profit before tax (PBT) and profit after tax (PAT) have also reached their highest in the last five quarters, with a positive trend in the near term.

Parmax Pharma has also shown an increase in its earnings per share (EPS), reaching its highest at Rs 0.03 in the last five quarters. This indicates that the company has been able to create higher earnings for its shareholders.

However, one area of concern for Parmax Pharma is its debtors turnover ratio, which has reached its lowest at 6.08 times in the last five half-yearly periods. This suggests that the company’s pace of settling its debtors has slowed down.

Overall, Parmax Pharma has shown a positive trend in its financial performance for the quarter ending March 2024. With its strong sales and profitability, the company is poised for growth in the near future.